Condition: Thalassemia, Beta · Sponsor: Bioray Laboratories
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
This description comes directly from the study's public registry record.
Rongmei Liang, phD · 021-64340008 · rongmeiliang@brlmed.com
Always discuss trial participation with your own doctor first.
| Nanfang Hospital, Southern Medical University | Guangzhou, Guangdong, China | Active Not Recruiting |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Shenzhen Children 's Hospital | Shenzhen, Guangdong, China | Not Yet Recruiting |
| No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital | Nanning, Guangxi, China | Not Yet Recruiting |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| Tianjin Institute of Hematology | Tianjin, Tianjin Municipality, China | Recruiting |
| The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY | Guangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06298630